News >

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Sep 18, 2019

The FDA has approved apalutamide (Erleada) for the treatment of patients with metastatic castration-sensitive prostate cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x